Tissue Procurement

组织采购

• 批准号: 10626986
• 负责人: Brooke E Howitt
• 金额: $ 21.49万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-04 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626986
• 关键词: Accountability; Achievement; Area; Autopsy; Biological Assay; Blood; Blood Banks; Blood specimen; Budgets; Cancer Biology; Cancer Center Support Grant; Cancer Model; Cancer Patient; Cell Survival; Cells; Clinic; Collaborations; Confidentiality of Patient Information; Consent; Consent Forms; Data; Databases; Electronics; Ensure; Flow Cytometry; Formalin; Fostering; Freezing; Fresh Tissue; Funding; Genetic; Genomics; Goals; Histologic; Human; Immunoassay; Immunologic Monitoring; Institution; Institutional Review Boards; Joints; Link; Malignant Neoplasms; Modeling; Normal tissue morphology; Operative Surgical Procedures; Organoids; Paraffin Embedding; Pathologic; Pathologist; Patients; Precision Health; Process; Protocols documentation; Publications; Radiation Oncology; Regulation; Research; Research Institute; Research Personnel; Resource Sharing; Services; Source; Specimen; Stains; Standardization; Surgical Pathology; Suspensions; Technology; Therapeutic; Tissue Banks; Tissue Embedding; Tissue Procurements; Tissue Sample; Tissues; Tumor Tissue; anticancer research; biobank; cancer genomics; cancer stem cell; cellular imaging; data access; data integration; experience; histological stains; human tissue; improved; individual patient; member; molecular imaging; neoplasm registry; programs; single-cell RNA sequencing; stem; surgery material

PROJECT SUMMARY The overall objective of the Tissue Procurement Shared Resource (TP-SR) is to procure and provide human tissue specimens to Stanford Cancer Institute (SCI) members to support their cancer-relevant research. TP-SR activities and services include collecting and banking freshly-frozen tumor and normal tissue from excess surgical material and from an autopsy, providing fresh tumor tissue for viable cell studies, processing and banking blood specimens from cancer patients, maintaining a tissue database with links to clinicopathological data, providing histological staining and pathological review services, coordinating patient consent, and assuring regulatory compliance. As a centralized shared resource, the TP-SR adds value through experience, efficiency, standardization, accountability, protection of patient confidentially, and timely completion of the research. From 2015 to 2020, the TP-SR consented over 11,000 patients, using universal consent and provided over 8,000 tissue and blood specimens to support cutting-edge cancer research in diverse areas, including cancer genomics, cancer stem, cells, and molecular imaging. The TP-SR also provides a data feed to the Stanford Cancer Institute Research Database (SCIRDB) to enable researchers to access data integration from many sources, including EPIC EHR, STARR, specialized databases in surgical pathology, and radiation oncology, and the Stanford Cancer Registry. The following are some of the TP-SR achievements. (1) The TP-SR established a collaboration with the Human Immune Monitoring Shared Resource (HIMC-SR), enabling obtaining single-cell suspensions of freshly procured surgical specimens. Over 300 fresh tissue specimens were processed in this way, fulfilling increasing demands for specimens that can be used for Immunoassays, CyTOF, flow cytometry, and genomic assays. (2) The TP-SR started providing consenting support and tissue collections for NCI’s Human Cancer Models Initiative. To date, the TP-SR has provided tissue and blood samples from more than 120 patients to this project. (3) The TP-SR started the process of merging patient consenting efforts with the Precision Health Biobank at Stanford. This initiative enables the TP-SR to capture more patients and eases the consenting burden of individual patients. (4) The TP-SR established a new protocol for electronic patient consenting via iPad—a joint effort with the Precision Health Biobank, which will allow for the consenting of a broader range of patients and improve the opportunity for clinic-based consenting. Members of all programs regularly use the TP-SR, with the heaviest use coming from the Cancer Biology and Cancer Stem Cells and Cancer Therapeutics programs. In 2020, 80% of users were SCI investigators. The TP- SR contributed to 40 cancer-focused publications (18 high-impact). The annual budget of the TP-SR is $787,997, yet the CCSG request is $248,725. Accordingly, the TB-SR leverages institutional support and seeks 32% from CCSG funds.

项目概要 组织采购共享资源 (TP-SR) 的总体目标是采购和提供人力 向斯坦福癌症研究所 (SCI) 成员提供组织标本，以支持他们的癌症相关研究。 活动和服务包括收集和储存多余的新鲜冷冻肿瘤和正常组织 手术材料和尸检结果，为活细胞研究、处理和储存提供新鲜的肿瘤组织 来自癌症患者的血液样本，维护一个包含临床病理数据链接的组织数据库， 提供组织学染色和病理学审查服务，协调患者同意，并确保 作为集中式共享资源，TP-SR 通过经验、效率、 标准化、问责制、保护患者机密以及及时完成研究。 2015 年至 2020 年，TP-SR 使用普遍同意的方式获得了超过 11,000 名患者的同意，并提供了超过 8,000 组织和血液样本支持包括癌症在内的不同领域的尖端癌症研究 TP-SR 还向斯坦福大学提供数据源，包括基因组学、癌症干细胞、细胞和分子成像。 癌症研究所研究数据库 (SCIRDB) 使研​​究人员能够访问来自多个领域的数据集成 来源，包括 EPIC EHR、STARR、外科病理学和放射肿瘤学专业数据库，以及 以下是 TP-SR 的一些成就 (1) TP-SR 的建立。 与人类免疫监测共享资源（HIMC-SR）合作，能够获得单细胞 在此处理了 300 多个新鲜手术标本的悬浮液。 满足对可用于免疫测定、CyTOF、流式细胞术、 (2) TP-SR 开始为 NCI 的人类提供同意支持和组织收集。 迄今为止，TP-SR 已提供了 120 多名患者的组织和血液样本。 (3) TP-SR 启动了将患者同意工作与 Precision Health 合并的过程。 斯坦福大学生物样本库的这一举措使 TP-SR 能够捕获更多患者并减轻同意负担。 (4) TP-SR 制定了通过 iPad 进行电子患者同意的新协议——a 与 Precision Health Biobank 共同努力，这将获得更广泛患者的同意 并增加基于临床的同意的机会。 所有项目的成员都定期使用 TP-SR，其中使用最多的是癌症生物学和 2020 年，80% 的用户是 TP- 癌症干细胞和癌症治疗项目。 SR 发表了 40 种以癌症为重点的出版物（其中 18 种具有高影响力）。 TP-SR 的年度预算为 787,997 美元。 然而 CCSG 的要求是 248,725 美元，因此，TB-SR 利用机构支持并寻求 32%。 CCSG 资金。